Ovagen, a synthetic peptide bioregulator, supports liver health by normalizing liver function and reducing inflammation and shows the potential to inhibit HIV replication. (PMID: 9485357)
Ovagen Research Topics:
-
HIV Management:
Emerging research suggests that Ovagen may inhibit the replication of HIV. This potential antiviral effect makes Ovagen a subject of interest for HIV researchers looking to understand and control the virus’s lifecycle more effectively. (PMID: 9485357)
Structure
Amino Acid Sequence: Glu-Asp-Leu (EDL) Molecular Formula: C1sH2sN3Oa
Molecular Weight: 375.37 g/mol
PubChem CID: 444128
Synonyms: EDL, glutamyl-aspartyl-leucine, SCHEMBL5329396, la30, CHEBl:137252
Source: PubChem
Ovagen and the Liver
According to research from Dr. Khavinson, Ovagen is a bioregulator of the GI tract and liver. In the liver, it has been found to promote cell proliferation and prevent scarring and fibrotic changes that can lead to cirrhosis. In the GI tract, Ovagen helps to boost mucosal barrier function and reduces complications from antibiotic treatment, environmental insults, chemotherapy, malnutrition, and more.
Like most bioregulators, the most robust effects of Ovagen are seen in older individuals. The peptide appears to roll back DNA changes that occur with age, helping to reset the DNA in liver fibroblasts and GI mucosal cells to a more youthful state. In this more youthful state, the DNA is less condensed, and therefore more genes are available for transcription. This results in a more functional cell that is less senescent and therefore “healthier.”
Research shows that Ovagen is well tolerated and may be useful in normalizing the function of the liver and GI tract in many different inflammatory and disease conditions. It may also be useful in the postoperative setting, during long-term antibiotic therapy, for overcoming the side effects of cancer treatments, and even as a diabetes preventative. Research on the GI and liver effects of Ovagen is ongoing.
Ovagen and HIV
The HIV-1 protease is an enzyme necessary for the HIV to survive. It functions to cleave newly synthesized proteins that make up the mature HIV virion. This infectious form of HIV will not function without the HIV-1 protease. In other words, the enzyme is essential for HIV to be able to infect more cells. Without the protease, HIV produces non-infectious progeny and dies out. Some HIV protease inhibitors are currently FDA-approved and used in treatment. Unfortunately, the virus’s high mutation rate results in relatively rapid formation of resistance.
Research on Ovagen reveals that it is an effective HIV-1 protease inhibitor. It is one of the smallest and most potent protease inhibitors known with an effective concentration of just 50 microns. Unlike other protease inhibitors, Ovagen is highly soluble in water [1]. This latter fact makes it easier to administer.
Ovagen Summary
Ovagen is a tripeptide bioregulator with primary effects in the liver and GI tract. Though research on this Khavinson peptide is limited at this point, it has shown promise as a potential anti-aging peptide in the liver and GI tract. Ovagen reduces long-term fibrosis in the liver and helps to protect the GI mucosal layer from the effects of antibiotics, environmental toxins, and even chemotherapy. There is also interest in the ability of Ovagen to inhibit the replication of HIV.
Article Author
The above literature was researched, edited, and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Scientific Journal Author
Vladimir Khavinson is a Professor, resident of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental, and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying the role of peptides in the regulation of the mechanisms of ageing. His main field of action is the design, pre-clinical, and clinical studies of new peptide geroprotectors. A 40-year investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of aging and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological Aspects of Genome Peptide Regulation” (Karger AG, 2005). Vladimir Khavinson introduced the scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversight over 200 Ph.D. and Doctorate theses from many different countries.
Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Ovagen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Life Link Research and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
